lifestyle.folsomlocalnews.com/

Author: Sagimet Biosciences Inc.

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 13, 2026
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 12, 2026
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago

May 11, 2026
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

April 27, 2026
Sagimet Biosciences Provides Strategic and Corporate Updates

April 27, 2026
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

April 20, 2026
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 6, 2026
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

March 11, 2026
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

February 25, 2026
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

February 11, 2026